Loading clinical trials...
Loading clinical trials...
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Conditions
Interventions
ALX1-11 (drug)
Locations
132
United States
'The University of Alabama at Birmingham
Birmingham, Alabama, United States
'Rheumatology Associates of North Alabama
Huntsville, Alabama, United States
'Radiant Research - Phoenix North
Phoenix, Arizona, United States
'Osteoporosis Medical Center
Beverly Hills, California, United States
'East Bay Clinical Trial Center
Concord, California, United States
'Loma Linda Osteoporosis Research Center
Loma Linda, California, United States
Start Date
October 16, 2001
Primary Completion Date
April 13, 2005
Completion Date
April 13, 2005
Last Updated
May 17, 2021
NCT06558188
NCT06449742
NCT07474571
NCT06541548
NCT07254429
NCT07412782
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions